University of California, San Francisco
ucsf.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
2,140
Active
463
Phase 3
89
Total enrollment
11,809,025
Pipeline matrix
Showing 40 of 188 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Azithromycin | — | — | — | — | 21 | ||
| Normal saline | — | — | 5 | ||||
| Dupilumab | — | — | — | — | — | 4 | |
| Guselkumab | — | — | — | — | — | 3 | |
| Infliximab | — | — | — | 3 | |||
| Sodium chloride | — | — | — | — | — | 2 | |
| Upadacitinib | — | — | — | — | — | 2 | |
| Deucravacitinib | — | — | — | — | — | 2 | |
| cyclosporine | — | — | — | 4 | |||
| Ocrelizumab | — | — | — | — | 3 | ||
| 5-fluorouracil | — | — | 5 | ||||
| Amoxicillin | — | — | — | — | 4 | ||
| Trimethoprim-sulfamethoxazole | — | — | — | — | 3 | ||
| Phenylephrine | — | — | — | — | 3 | ||
| Azithromycin for Oral Suspension | — | — | — | — | — | 3 | |
| Mirabegron | — | — | — | — | — | 2 | |
| Losartan | — | — | — | — | 2 | ||
| Albuterol | — | — | — | — | 2 | ||
| Tildrakizumab | — | — | — | — | — | 2 | |
| Lemborexant | — | — | — | — | — | 2 | |
| indomethacin | — | — | — | — | 2 | ||
| Oral Methamphetamine | — | — | — | — | — | 2 | |
| Secukinumab | — | — | — | — | — | 2 | |
| Ustekinumab | — | — | — | — | — | 2 | |
| Norepinephrine | — | — | — | — | — | 2 | |
| Ruxolitinib | — | — | — | — | 2 | ||
| Magnesium sulfate administration | — | — | — | — | — | 1 | |
| Injectable buprenorphine | — | — | — | — | — | 1 | |
| Sublingual Buprenorphine | — | — | — | — | — | 1 | |
| Tolterodine Tartrate ER | — | — | — | — | — | 1 | |
| Doxycycline 40 MG | — | — | — | — | — | 1 | |
| Doxycycline 200 MG | — | — | — | — | — | 1 | |
| Dropless Regimen | — | — | — | — | — | 1 | |
| Standard Regimen | — | — | — | — | — | 1 | |
| Dolutegravir | — | — | — | — | — | 1 | |
| Emtricitabine/Tenofovir | — | — | — | — | — | 1 | |
| Hormone Replacement Therapy | — | — | — | — | — | 1 | |
| Corticosteroid and 1%lidocain | — | — | — | — | — | 1 | |
| Tildrakizumab Prefilled Syringe | — | — | — | — | — | 1 | |
| Letrozole 2.5mg | — | — | — | — | — | 1 |
148 more active programs hidden
Next readouts
- 2023-01-31
- 2024-08-01
- 2024-12-31
- 2025-01-16
- 2025-01-30
- 2025-07-11
- 2025-12-31
- 2026-01-07
- 2026-03-18
- 2026-04
Top conditions
- HIV62
- HIV Infections56
- Prostate Cancer45
- Breast Cancer42
- Depression40
- Healthy36
- HIV/AIDS32
- Asthma31
Frequently asked questions about University of California, San Francisco
- How many clinical trials does University of California, San Francisco have on ClinicalTrials.gov?
- University of California, San Francisco is listed as the lead sponsor on 2,140 clinical trials in ClinicalTrials.gov, 463 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, San Francisco's trials are in Phase 3?
- 89 of University of California, San Francisco's trials are in Phase 3, spread across 188 active drug programs.
- What therapeutic areas does University of California, San Francisco focus on?
- University of California, San Francisco's most-studied conditions on ClinicalTrials.gov are HIV, HIV Infections, Prostate Cancer, Breast Cancer, Depression.
- When are University of California, San Francisco's next clinical trial readouts?
- University of California, San Francisco has 10 upcoming primary-completion readouts tracked here; the soonest is “Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery”, expected around 2023-01-31.